NasdaqGS:IBRXBiotechs
ImmunityBio Wins EU Anktiva Nod As Investors Weigh Execution Risks
ImmunityBio's lead oncology drug Anktiva has received conditional marketing authorization from the European Commission for bladder cancer, opening commercial access across 33 countries.
The company is also securing accelerated approvals and advancing regulatory expansion in Saudi Arabia, adding to its international footprint.
These regulatory decisions expand ImmunityBio's commercial reach in bladder cancer treatment across Europe and the Middle East.
For investors tracking ImmunityBio...